Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 4/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 6/20 | 0.33 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26117812 | 0.81 | ALDH1A1 (0.33) | MPOXDHGRIN2DGRIN3BGRIN1 | |
| SCHEMBL27783885 | 0.77 | MPO (0.44) | MPOXDHGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6471981 | 0.77 | MAPK1 (0.44) | ALDH1A1MAPK1 | |
| SCHEMBL4261833 | 0.68 | GRIN2D (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22114480 | 0.67 | CYP1A2 (0.52) | ALDH1A1GAAMEN1KMT2APKM | |
| SCHEMBL28372858 | 0.66 | TDP1 (0.52) | MPOXDHGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5792152 | 0.63 | CRBN (0.42) | ALDH1A1CA1CA2CA9PKM | |
| SCHEMBL17372112 | 0.63 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL355904 | 0.63 | MPO (0.38) | MPOXDHALDH1A1GAAHSD17B10 | |
| SCHEMBL22114414 | 0.62 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 671 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3291799-A1 | NUCLEIC ACID-CATIONIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-03-14 | — | — | EP | claimed |
| WO-2016178233-A1 | NUCLEIC ACID-CATIONIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-11-10 | — | — | WO | claimed |
| WO-2014152909-A1 | ALTERATION OF GENE EXPRESSION BY SYNTHETIC piRNAs AND BY ALTERATION OF piRNA FUNCTION | IBIS BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026107236-A1 | COMPOSITIONS AND METHODS FOR VACCINATION AGAINST MYCOBACTERIUM TUBERCULOSIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260117254-A1 | COMPOSITIONS AND METHODS FOR PREPARING VIRAL VECTORS | NIKEGEN LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109937-A1 | ENGINEERED MICROORGANISMS WITH ENHANCED PROTEIN EXPRESSION AND SECRETION | UNIV NORTH CAROLINA STATE (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260097120-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | PHIO PHARMACEUTICALS CORP. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12582675-B2 | Methods for treatment of cancers harboring an H3K27M mutation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12544344-B2 | Topical delivery of nucleic acid compounds | PHIO PHARMACEUTICALS CORP. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260022188-A1 | Compositions and Methods for Inhibiting T Cell Exhaustion | UNIV LELAND STANFORD JUNIOR (US) | 2026-01-22 | — | — | US | disclosed |
| EP-0539371-A1 | TRIPLE HELIX FORMATION IN OLIGONUCLEOTIDE THERAPY | GILEAD SCIENCES, INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| EP-0498843-A4 | OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES | — | 1992-11-04 | — | — | EP | disclosed |
| WO-1992014842-A1 | APTAMERS SPECIFIC FOR THROMBIN AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992014843-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0498843-A1 | OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES. | GILEAD SCIENCES INC (US) | 1992-08-19 | — | — | EP | disclosed |
| WO-1992010590-A1 | INHIBITION OF TRANSCRIPTION BY FORMATION OF TRIPLE HELIXES | GILEAD SCIENCES, INC. (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992009705-A1 | TRIPLEX-FORMING OLIGOMERS CONTAINING MODIFIED BASES | GILEAD SCIENCES, INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992005186-A1 | MODIFIED INTERNUCLEOSIDE LINKAGES | GILEAD SCIENCES (US) | 1992-04-02 | — | — | WO | disclosed |
| WO-1991006626-A2 | TRIPLE HELIX FORMATION IN OLIGONUCLEOTIDE THERAPY | GILEAD SCIENCES, INC. (US) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022188-A1 | Compositions and Methods for Inhibiting T Cell Exhaustion | JUND, NFATC1, ICOS | MPO 4733/4885XDH 4361/4885GRIN2D 3321/4885 |
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | TP53, CD74, HLA-C | MPO 4374/4885XDH 2448/4885GRIN2D 3989/4885 |
| US-20260097120-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | CD274, PDCD1LG2, ICOS | MPO 3459/4885XDH 1355/4885GRIN2D 4248/4885 |
| US-20260117254-A1 | COMPOSITIONS AND METHODS FOR PREPARING VIRAL VECTORS | PHAX, HM13, DNA2 | MPO 3857/4885XDH 922/4885GRIN2D 3001/4885 |
| US-20260109937-A1 | ENGINEERED MICROORGANISMS WITH ENHANCED PROTEIN EXPRESSION AND SECRETION | PMM2, PGAM1, PGM2 | MPO 3290/4885XDH 2996/4885GRIN2D 4624/4885 |
| US-12582675-B2 | Methods for treatment of cancers harboring an H3K27M mutation | H1-2, CARM1, H1-3 | MPO 4442/4885XDH 4691/4885GRIN2D 462/4885 |
| US-12544344-B2 | Topical delivery of nucleic acid compounds | METTL16, NSUN2, RNMT | MPO 3322/4885XDH 2380/4885GRIN2D 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.